Praxis Precision Medicines and Remagine Labs Announce Strategic Collaboration to Develop Transdermal Ulixacaltamide for Essential Tremor
Praxis Precision Medicines announced a strategic collaboration with Remagine Labs to develop a transdermal patch for its lead asset, ulixacaltamide, targeting essential tremor. The partnership aims to expand the addressable market and extend the franchise value by offering a differentiated delivery option alongside the oral formulation currently under FDA review.
Key figures
- Drug Name
- ulixacaltamide
- Pdufa date
- January 29, 2027
- Et population us
- 7 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.